Edilberto P. Calma

Edilberto P. Calma serves as a key procurement lead at the Naval Medical Research Center, supporting the Department of the Navy’s mission to enhance force health protection through advanced biomedical innovation. He manages complex acquisitions for diagnostic technologies, laboratory instrumentation, and field-deployable medical systems critical to operational readiness in austere environments. His portfolio centers on high-stakes R&D and manufacturing contracts that enable rapid pathogen detection, precision monitoring, and analytical tool development for Navy and Marine Corps personnel, aligning closely with the agency’s strategic focus on translational medical science and expeditionary healthcare solutions. Calma maintains a primary working relationship with REES SCIENTIFIC CORPORATION, a trusted vendor specializing in analytical laboratory instrumentation and in-vitro diagnostic systems. His contracting patterns reflect a preference for established technical partners with proven capabilities in biomedical engineering and regulatory-compliant manufacturing, fostering long-term collaborations that ensure reliability and rapid deployment of mission-critical medical technologies. While he engages with a limited pool of core contractors, his approach emphasizes technical alignment, performance history, and compliance with military specifications over broad vendor diversification. His procurement activity is overwhelmingly non-set-aside, with 94.8% of awards issued under full and open competition, reflecting the specialized nature of the technologies required. Small business participation is modest but intentional, with targeted support for Women-Owned Small Businesses and Total Small Business Set-Asides under FAR 19.5, and minimal use of Service-Disabled Veteran-Owned Small Business set-asides, indicating a focus on capability over socioeconomic preference unless explicitly warranted by technical need. Calma’s primary NAICS focus lies in Analytical Laboratory Instrument Manufacturing (334516) and In-Vitro Diagnostic Substance Manufacturing (325413), underscoring his expertise in procuring lab-based diagnostic platforms, biosensors, and reagent systems for infectious disease surveillance. He also frequently acquires services under Research and Development in the Life Sciences (541712), demonstrating deep engagement with cutting-edge biomedical innovation cycles and the transition of prototype technologies into operational use.